Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of sideroblastic anemia arised in multiple myeloma is related. Eighteen cases of literature are studied. This evolution usually appears in old and remitted myeloma. The pathogeny of the sideroblastic anemia is unknown, and possibly related to leukemia complicating multiple myeloma.
 ...
PMID:[Sideroblastic anemia in a multiple myeloma treated by melphalan (author's transl)]. 23 36

The authors report the association of a refractory sideroblastic anemia and a "non-excreting" plasma cell myeloma. The anemia was observed 8 years before the onset of the myeloma, which had typical hematological characteristics. Both kappa and gamma light chains were found in the cytoplasm and on the surface of the plasma cells. Pathologic characteristics of this type of myeloma are briefly recalled, as well as the relationships between sideroblastic anemia and kahler's disease, an example of disorders of two lines of hematopoiesis (erythrocytes and leucocytes).
 ...
PMID:["Non-secreting" plasma cell myeloma preceded by refractory sideroblastic anemia (author's transl)]. 23 75

Of 476 patients with multiple myeloma treated during a 9-year period, 11 developed acute myelogenous leukemia or sideroblastic anemia. In all, the myeloma was in remission from chemotherapy with melphalan-prednisone combinations that had been continued for a median duration of 3 years. The incidence of acute leukemia or sideroblastic anemia was about 100 times higher than found in normal individuals of the same age. In all patients studied, major cytogenetic abnormalities were present, with hypodiploidy and evidence of chromosomal damage being noted most frequently. The frequency and nature of the chromosome changes were attributed to effects resulting from the prolonged drug therapy. These findings supported the long-term follow-up of selected patients with myeloma without any chemotherapy when marked degrees of remission followed the initial treatment courses.
 ...
PMID:Acute leukemia in multiple myeloma. 40 40

A 67-year-old female was admitted to our hospital because of pancytopenia. Forty-six percent of erythroblasts in the bone marrow were ringed sideroblasts. Laboratory findings showed an IgG-kappa monoclonal gammopathy. She was diagnosed as having sideroblastic anemia associated with multiple myeloma in mosaic (45, X/46, XX/47, XXX) Turner's syndrome. There was no response to therapy. The chromosomal pattern of the patient was varied, and was accompanied by the development of refractory anemia with an excess of blasts from refractory anemia with ringed sideroblast 4 months after presentation. Cytogenetic studies suggested that the abnormal clone was restricted to the monosomic cell line.
 ...
PMID:Sideroblastic anemia associated with multiple myeloma in Turner's syndrome. 163 53

Five patients with myeloproliferative disorders and paraprotein are reported. The diseases included acute myelomonocytic leukemia, chronic myeloid leukemia, sideroblastic anemia with excess of blasts, polycythemia vera and myelofibrosis. In four cases, the paraprotein was of the IgG k type and in one, IgM k. No evidence of multiple myeloma or excessive plasmacytosis was noted. The literature records 19 other myeloid disorders with this unusual association. Although the pathogenesis remains unclear, three possible explanations are suggested: disturbance of the pluripotent stem cell resulting in a combined myeloplasmatic disorder, coexistence of two diseases, or a fortuitous association.
 ...
PMID:Myeloproliferative disorders and nonmyelomatous paraprotein. A study of five patients and review of the literature. 394 87

Five patients with mucormycosis of the heart are described. Two had leukemia,, one had multiple myeloma, one sideroblastic anemia, and one had been wounded when a body trap exploded. None had diabetes. In addition to heart involvement, each had mucormycosis of the lungs. Kidney was infected in two patients and gastrointestinal tract, spleen, liver, adrenal, brain, and skin were each involved in one patient. Three patients had cardiac symptoms. The findings in ten previously reported patients with de novo cardiac mucormycosis and in four patients with mucormycosis occurring in association with cardiovascular surgery are summarized.
 ...
PMID:Cardiac mucormycosis. A report of five patients and review of 14 previously reported cases. 710 6

Anemia is the most frequent peripheral cytopenia observed in myelodysplastic syndromes (MDS) and has been recognized among the most important factors affecting the outcome of patients with MDS. In patients who are not candidates for potentially curative approaches, therapeutic options for symptomatic anemia include red blood cell (RBC) transfusion and iron chelation, hematopoietic growth factors, immunosuppression, immune-modulatory drugs, and hypomethylating agents. In about 40% of patients, regular RBC transfusions are the only therapeutic option that can be offered. The onset of a regular transfusion requirement significantly worsens the survival of patients with MDS. Transfusion-dependent patients invariably develop secondary iron overload. Elevated serum ferritin was proven to be associated with worse survival in transfusion-dependent patients, and recent data obtained using magnetic resonance imaging show both hepatic and myocardial iron accumulation in heavily transfused patients. According to evidence-based guidelines, patients with sideroblastic anemia, 5q- syndrome, or other forms of refractory anemia, in whom long-term transfusion therapy is likely, are recognized as the best candidates to receive iron chelation therapy. In addition, patients who are candidates for allogeneic stem cell transplantation might also benefit from chelation therapy because iron overload is associated with increased transplantation-related mortality. RBC transfusions and iron chelation are the mainstay of therapy for many individuals with MDS. However, critical issues remain to be clarified in order to optimize treatment, including the identification of target hemoglobin levels to prevent anemia-related morbidity and more accurate information on the effect of iron-mediated organ damage on the outcome of patients with MDS.
Clin Lymphoma Myeloma 2009
PMID:Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. 1977 58